T1	Participants 10 88	rheumatoid arthritis patients of Shen deficiency and cold invading syndrome by
T2	Participants 423 559	RA patients of Shen deficiency and cold invading syndrome in the treatment group (120 cases) were treated with BQZD and MTX (10 mg/week)
T3	Participants 580 647	control group (120 cases) were treated with MTX (10 mg/week) alone.
T4	Participants 1900 1958	RA patients of Shen deficiency and cold invading syndrome.
